This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Consumer Stock Takeovers: Deals and Targets

Billionaire Carl Icahn stepped up his proxy fight for Clorox (CLX - Get Report). On Aug. 30 he said he would backstop an auction for the cleaning supplies maker, hoping to obtain $78 per share, if the board members he nominated were elected. If the auction fails to bring in an offer at that price then he will buy the company himself at that rate, valuing the company at $10.26 billion.

Clorox had twice rejected Icahn's acquisition bids; in mid-July he offered $76.50 per share, and then raised his offer to $80 per share. Clorox then adopted a shareholder rights plan, which amounts to a "poison pill" that protects against hostile buyers through share dilution. Clorox's most recent takeover rejection came as the company questions Icahn's ability to fund the acquisition. Icahn said Tuesday he would fund half of the purchase with cash with the remainder funded through registered senior unsecured notes. He has said recently that he had a "highly confident" financing letter from Jefferies Group.

Clorox's board and shareholders would still vote on the deal, Icahn said. "The Clorox shareholders should have the right to decide for themselves whether to accept my bid or a better bid which I believe will be forthcoming from the sale process," he said Tuesday. Icahn already owns around 9.4% of Clorox.

On Aug. 19 Icahn made clear his plans to take control of all the seats on Clorox's board, intending to nominate himself, his son and nine others for election to the company's board at its next annual shareholder meeting, the date of which has yet to be set.

"When you try to seek control [of a company's board, rather than nominating a minority slate], the focus becomes what you'll do with control as opposed to the failings of the earlier management team," Charles Elson, director of the University of Delaware's Weinberg Center for Corporate Governance, told Reuters at the time.

Icahn's original proposal was widely viewed as merely a way to put Clorox in play. Entities controlled by Icahn own roughly 9.4% of Clorox's outstanding common stock, making him the company's largest shareholder. He tapped consumer products makers Procter & Gamble (PG - Get Report), Unilever (UN), Kimberly-Clark (KMB) and Colgate-Palmolive (CL) as possible "strategic buyers" that might offer "superior bids." "We are in a unique position as your largest shareholder in that we are wearing two hats -- one as a shareholder and another as a buyer," Icahn wrote in his July 15 letter.
6 of 25

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CLX $124.38 0.00%
GOOG $683.57 0.00%
PG $81.20 0.00%
PEP $97.32 0.00%
UN $42.73 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs